THE KED PEPTIDE REGULATES THE SYNTHESIS OF SIGNAL MOLECULES – MARKERS OF ADHESION AND REGULATORS OF TROMBOGENESIS IN INTACT AND DAMAGED VASCULAR ENDOTHELIUM

DOI: https://doi.org/10.29296/24999490-2018-01-10

I.I. Bolotov (1), K.L. Kozlov (1), A.O. Drobintseva (2), I.B. Antonov (1), N.S. Linkova (1, 3) 1-Saint Petersburg Institute of Bioregulation and Gerontology, Dinamo pr., 3, Saint Petersburg, 197110, Russian Federation; 2-Ott Institute of Obstetrics, Gynecology and Reproductology, Mendeleevskaya line 3, Saint Petersburg, 199034, Russian Federation; 3-Peter the Great Saint Petersburg Polytechnic University, Polytechnicheskaya str. 29, Saint Petersburg, 195251, Russian Federation E-mail: [email protected]

Introduction. The investigation of molecular and cellular mechanisms of atherosclerosis and the development of restenosis and the possibility of the regulation of these processes by short peptides opens new perspectives for the delivery of vasoprotective preparations. The aim of work is to investigate the influence of the KED peptide on the expression of signal molecules – markers of trombogenesis and antithrombotic factors in vascular endothelium in vitro, in intact vessels, atherosclerosis and restenosis. Methods. There were used primary endothelial cell cultures, obtained from embryo human aortae and atherosclerosis and restenosis aortae of elderly patients during aortocoronary shunting operations. The investigation of the expression of signal molecules by endothelium was made by immunofluorescence confocal methods with quantitative data analysis by the morphometric method. Results. The KED peptide decreased the Willebrand factor (vWF) expression in endothelial cultures with atherosclerosis and restenosis correspondingly by 2,2 and 2,3 times. The KED peptide decreased fibronectin expression in endothelial cultures with atherosclerosis and restenosis correspondingly by 5,5 and 4,6 times, which was low in comparison with control endothelium cell cultures. The KED peptide increased tissue types plasminogen activator (tPA) expression in endothelium cell cultures with restenosis by 2,2 times and hasn’t such effect in endothelial cultures with atherosclerosis. The KED peptide increased trombomodulin (CD141) expression by 2,7 times in endothelial cultures with atherosclerosis and by 2,5 times in endothelium cell cultures with restenosis. Conclusion. The KED peptide was shown to decrease the expression of proteins – markers of adhesion and platelets aggregation (vWF, fibronectin) in vascular endothelium and stimulated synthesis of molecules possessing of antithrombotic effects (tPA, CD141). The KED peptide can be potent as the perspective drug for the treatment and prevention of atherosclerosis and restenosis.
Keywords: 
KED peptide, aortae endothelium cell culture, atherosclerosis, restenosis, trombogenesis

Список литературы: 
  1. Soldatov V.M., Kozlov K.L., Lin`kova N.S. Vozrastnye osobennosti e`kspressii signal`nyh molekul v e`ndotelii sosudov cheloveka i ih rol` v razvitii serdechno-sosudistoy patologii. Molekulyarnaya medicina. 2015; 6: 33–7.
  2. [Soldatov V.M., Kozlov K.L., Linkova N.S. Age-dependent special aspects signal molecules expression in human vessel endothelium and its role in cardio-vascular pathology development. Molecular medicine. 2015; 6: 33–7 (in Russian)]
  3. Kozlov K.L., Soldatov V.M., Polyakova V.O., Lin`kova N.S., Durnova A.O., Medvedev D.S. Molekulyarnye aspekty stareniya sosudov in vitro. Molekulyarnaya medicina. 2015; 3: 53–6.
  4. [Kozlov K.L., Soldatov V.M., Polyakova V.O., Linkova N.S., Durnova A.O., Medvedev D.S. Molecular aspects of in vitro vessels aging. Molecular medicine. 2015; 3: 53–6 (in Russian)]
  5. Pal`cev M.A., Soldatov V.M., Kozlov K.L., Pal`ceva E.M., Lin`kova N.S., Polyakova V.O., Sedova E.V., Mursalov S.U., Kvetnoy I.M. E`kspressiya signal`nyh molekul v e`ndotelii aorty pri starenii i ateroskleroze. Molekulyarnaya medicina. 2015; 5: 12–5.
  6. [Paltsev M.A., Soldatov V.M., Kozlov K.L., Paltseva E.M., Linkova N.S., Polyakova V.O., Sedova E.V., Mursalov S.U., Kvetnoy I.M. Expression of aorta endothelium signal molecules during atherosclerosis and ageing. Molecular medicine. 2015; 5: 12–5 (in Russian)]
  7. Havinson V.H., Lin`kova N.S., Morozova E.A., Gutop E.O., Elashkina E.V. Molekulyarnye mehanizmy serdechno-sosudistoy patologii. Uspehi fiziologicheskih nauk. 2014; 45 (3): 57–63.
  8. [Khavinson V.Kh., Linkova N.S., Morozova E.A., Gutop E.O., Elashkina E.V. Molecular mechanisms of cardio-vascular diseases. Advances of physiological sciences. 2014; 45 (3): 57–63 (in Russian)]
  9. Kitachev K.V., Sazonov A.B., Kozlov K.L., Petrov K.Yu.., Slyusarev A.S., Sedova E.V. Rol` vazoaktivnogo peptida v lechenii hronicheskoy arterial`noy nedostatochnosti nizhnih konechnostey. Uspehi gerontologii. 2013; 26 (2): 292–6.
  10. [Kitachev K.V., Sazonov A.B., Kozlov K.L., Petrov K.Yu., Slusarev A.S., Sedova E.V. The role of vasoactive peptide in treatment of chronic arterial disorders of lower extremities. Adv Gerontol. 2013; 26 (2): 292–6 (in Russian)]
  11. Kitachev K.V., Sazonov A.B., Kozlov K.L., Petrov K.Iu., Sliusarev A.S., Khavinson V.Kh. The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people. Adv Gerontol. 2014; 27 (1): 156–9.
  12. Havinson V.H., Grigor`ev E.I., Malinin V.V., Ryzhak G.A. Peptid, povyshayushhiy rezistentnost` kapillyarov, farmacevticheskaya kompoziciya na ego osnove i sposob ego primeneniya. 2006. Patent RF №2295970.
  13. [Khavinson V.Kh., Grigoriev E.I., Malinin V.V., Ryzhak G.A. Peptide, increased capillary resistance, pharmaceutics composition on its base and the method of its using. 2006. Patent of the Russian Federation. N 2295970 (in Russian)]
  14. Khavinson V.Kh., Tarnovskaya S.I., Linkova N.S., Gutop E.O., Elashkina E.V. Epigenetic Aspects of Peptidergic Regulation of Vaslular Endothelial Cell Proliferation in Aging. Advances in Gerontology. 2015; 5 (4): 219–24.
  15. Khavinson V.Kh., Linkova N.S., Elashkina E.V., Durnova A.O., Kozlov K.L. Molecular Aspects of Anti-Atherosclerotic Effects of Short Peptides. Cell Technologies in Biology and Medicine. 2014; 158 (1): 159–63.
  16. Isakadze A., Burkadze N., Noniashvili M. The importance of risk factors in emergence and development of ishemic heart deasease. Georgian Medicine News. 2011; 11 (200): 56–9.
  17. Gurevich M.A., Sturov N.V. Deficit oksida azota i podderzhanie sosudistogo gomeostaza: rol` mononitratov i problemy citoprotekcii. Trudnyy pacient. 2010; 3: 23–9.
  18. [Gurevich M.A., Styrov N.V. Deficit of NO and support of vessel homeostasis: the role of mononitrats and problems of cytoprotectors. Difficult patient 2010; 3: 23–9 (in Russian)]
  19. Gyongyosi M., Glogar D., Weidinger F. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-ST-segment elevation myocardial infarction. Americam Heart J. 2004; 147 (1): 158–64.
  20. Chao T.H., Tsai W.C., Chen J.Y. Soluble thrombomodulin is a paracrine anti-apoptotic factor for vascular endothelial protection. International J. Cardiology. 2014; 0167-75.
  21. Montoro-García S., Shantsila E., Lip G.Y. Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease. Expert Opinion on Therapeutic Targets. 2014; 18: 43–53.